Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Jaguar Health (NASDAQ:JAGX) announced its participation in the 2025 Animal Health Summit with the goal of securing partnerships to expand Canalevia's indication from chemotherapy-induced diarrhea (CID) to general diarrhea treatment in dogs. Canalevia-CA1, their FDA conditionally approved plant-based drug, has reached 25% enrollment in its ongoing effectiveness study.
The company is in discussions with multiple potential animal health partners to achieve three key objectives: expanding U.S. indication to general diarrhea, obtaining EU approval, and maintaining U.S. availability for CID treatment. With an estimated 11 million dogs suffering from general diarrhea annually in the U.S. and a significant market in Europe's 104 million dog population, Jaguar sees substantial market potential.
Jaguar Health (NASDAQ:JAGX) ha annunciato la sua partecipazione all'Animal Health Summit 2025 con l'obiettivo di trovare partner per estendere l'indicazione di Canalevia da diarrea indotta da chemioterapia (CID) a trattamento della diarrea generale nei cani. Canalevia-CA1, il loro farmaco a base vegetale approvato condizionalmente dalla FDA, ha raggiunto il 25% dell'arruolamento nello studio di efficacia in corso.
L'azienda sta negoziando con diversi potenziali partner nel settore veterinario per perseguire tre obiettivi principali: estendere l'indicazione negli USA alla diarrea generale, ottenere l'approvazione in UE e garantire la disponibilità negli USA per il trattamento della CID. Con una stima di 11 milioni di cani affetti annualmente da diarrea generale negli USA e un mercato significativo nei 104 milioni di cani presenti in Europa, Jaguar individua un elevato potenziale commerciale.
Jaguar Health (NASDAQ:JAGX) anunció su participación en la Cumbre de Salud Animal 2025 con el objetivo de asegurar socios para ampliar la indicación de Canalevia de diarrea inducida por quimioterapia (CID) a tratamiento de diarrea general en perros. Canalevia-CA1, su fármaco de origen vegetal aprobado condicionalmente por la FDA, ha alcanzado el 25% de reclutamiento en su estudio de eficacia en curso.
La compañía está en conversaciones con varios posibles socios de salud animal para lograr tres objetivos clave: ampliar la indicación en EE. UU. a diarrea general, obtener la aprobación en la UE y mantener la disponibilidad en EE. UU. para el tratamiento de CID. Con un estimado de 11 millones de perros con diarrea general anualmente en EE. UU. y un mercado relevante en los 104 millones de perros en Europa, Jaguar ve un notable potencial de mercado.
Jaguar Health (NASDAQ:JAGX)는 Canalevia의 적응증을 화학요법 유발 설사(CID)에서 반려견 일반 설사 치료로 확대하기 위한 파트너십을 모색하고자 2025 동물건강 서밋에 참여한다고 발표했습니다. FDA 조건부 승인된 식물 유래 약물 Canalevia-CA1은 진행 중인 유효성 연구에서 25% 등록 완료를 기록했습니다.
회사는 미국 내 적응증을 일반 설사로 확대, EU 승인 획득, CID 치료를 위한 미국 내 가용성 유지라는 세 가지 주요 목표를 달성하기 위해 여러 잠재적 동물건강 파트너와 협의 중입니다. 미국에서 연간 약 1,100만 마리의 반려견이 일반 설사로 고통받고 유럽의 1억4백만 마리(104백만 마리) 반려견 시장이 있는 만큼 Jaguar는 상당한 시장 잠재력을 보고 있습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé sa participation au Animal Health Summit 2025 dans le but de sécuriser des partenariats pour étendre l'indication de Canalevia, de la diarrhée induite par chimiothérapie (CID) au traitement de la diarrhée générale chez le chien. Canalevia-CA1, leur médicament d'origine végétale approuvé conditionnellement par la FDA, a atteint 25% d'inclusion dans son étude d'efficacité en cours.
La société est en discussions avec plusieurs partenaires potentiels dans la santé animale pour atteindre trois objectifs clés : étendre l'indication aux États-Unis à la diarrhée générale, obtenir l'approbation dans l'UE et maintenir la disponibilité aux États-Unis pour le traitement de la CID. Avec une estimation de 11 millions de chiens souffrant chaque année de diarrhée générale aux États-Unis et un marché important parmi les 104 millions de chiens en Europe, Jaguar perçoit un fort potentiel commercial.
Jaguar Health (NASDAQ:JAGX) gab bekannt, dass das Unternehmen am Animal Health Summit 2025 teilnimmt, um Partnerschaften zu gewinnen, die die Indikation von Canalevia von chemotherapieinduzierter Diarrhö (CID) auf die Behandlung allgemeiner Diarrhöen bei Hunden ausweiten sollen. Canalevia-CA1, ihr von der FDA bedingt zugelassenes pflanzenbasiertes Medikament, hat in der laufenden Wirksamkeitsstudie 25% Einschreibung erreicht.
Das Unternehmen führt Gespräche mit mehreren potenziellen Tiergesundheitspartnern, um drei zentrale Ziele zu verfolgen: die Ausweitung der US-Indikation auf allgemeine Diarrhö, die Zulassung in der EU und die Sicherstellung der Verfügbarkeit in den USA für die CID-Behandlung. Bei schätzungsweise 11 Millionen Hunden mit jährlicher allgemeiner Diarrhö in den USA und einem bedeutenden Markt unter Europas 104 Millionen Hunden sieht Jaguar ein erhebliches Marktpotenzial.
- Enrollment reached 25% in ongoing effectiveness study for Canalevia-CA1
- Large market opportunity with 11 million dogs suffering from diarrhea annually in U.S.
- Potential EU approval pathway identified using existing study data
- Multiple veterinary distributors already carrying Canalevia-CA1 in U.S.
- Currently in discussions with multiple potential animal health partners
- Previous EU study did not meet its primary endpoint, requiring revised endpoint analysis
- Still requires full FDA approval for CID indication
- Partnership needed for further development and commercialization
Insights
Jaguar Health pursuing partnerships to expand Canalevia from cancer-specific to general dog diarrhea market, representing substantial revenue potential.
Jaguar Health is making strategic moves to significantly expand the market potential for Canalevia, their plant-based anti-diarrheal medication. The company is actively seeking partnerships at the upcoming Animal Health Summit to transform Canalevia from a niche product for chemotherapy-induced diarrhea (CID) in dogs to a treatment for general canine diarrhea – a substantial market upgrade.
The market opportunity here is compelling. With approximately 90 million dogs in the U.S. alone, Jaguar estimates that over 11 million suffer from general diarrhea annually. U.S. veterinarians reportedly see around 4 million cases of acute and chronic diarrhea in dogs each year. This represents a dramatic expansion from the current chemotherapy-specific indication.
Jaguar's three-pronged strategy involves: 1) expanding the U.S. indication to general diarrhea, 2) obtaining EU approval for general diarrhea using existing study data, and 3) maintaining Canalevia's availability for CID treatment. Their European strategy is particularly interesting – despite a previous study not meeting its primary endpoint, Jaguar has identified an alternative endpoint that shows statistical significance, which could potentially support EU approval.
The company has made measurable progress on their full effectiveness study for Canalevia-CA1, with enrollment reaching 25%. This study aims to collect real-world evidence to support full FDA approval for the CID indication.
What makes Canalevia particularly valuable in the veterinary pharmaceutical landscape is that it's not an antibiotic. With growing concerns about antibiotic resistance, a plant-based alternative that modulates chloride channels represents a differentiated approach to treating a common condition with no current FDA-approved medications for general cases.
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogs
Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally
Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs
Enrollment has reached approximately
SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced it is participating in the 2025 Animal Health Summit in support of the company's goal of securing a collaboration to expand the indication of Canalevia (crofelemer delayed-release tablets) from treatment of chemotherapy-induced diarrhea (CID) in dogs to treatment of general diarrhea in dogs. Canalevia, under the name Canalevia-CA1, is conditionally approved by the U.S. Food and Drug Administration (FDA) for treatment of CID in dogs. The Animal Health Summit, hosted by KC Animal Health Corridor, takes place August 25-26, 2025 in Kansas City, Missouri.
"I'm pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners regarding collaborating on the development, approval, and commercialization of Canalevia for treatment of general diarrhea in dogs," said Lisa Conte, Jaguar's Founder and CEO. "Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs; obtain approval in the European Union for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs. Forging a partnership to support these goals is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for Jaguar this year."
"Our goal is to be as comprehensive as possible in the search for the best partner for Canalevia - and with this goal in mind we look forward to participating in the 2025 Animal Health Summit. Our team is available for partnership discussions at the event," said David Sesin, PhD, Jaguar's Chief Manufacturing Officer.
A report by the American Veterinary Medical Foundation concluded that there were approximately 90 million dogs in the U.S. in 2024, of which Jaguar estimates more than 11 million suffer from general diarrhea each year. Data from the European Pet Food Industry Federation concluded that there were approximately 104 million dogs in Europe in 2022. "We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs in the U.S. and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general diarrhea in dogs - both in the U.S. and the EU," said Conte. "We estimate that U.S. veterinarians see approximately four million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general diarrhea in the U.S. and/or globally."
As announced, enrollment has begun in Jaguar's ongoing full effectiveness study of Canalevia-CA1 for the treatment of CID in dogs. With multiple veterinary oncology clinics signed on to take part in this study, enrollment has reached
Canalevia contains crofelemer, a plant-based botanical prescription drug that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics.
"In the EU, as we announced, it may be possible to obtain approval of Canalevia for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in 200 dogs with general diarrhea," Conte said. "While this completed trial did not meet its stated primary endpoint, the study results are clinically significant when analyzed using an alternate endpoint, defining treatment success as any dog that had no episodes of diarrhea following the first treatment with either Canalevia or placebo. Using this revised endpoint, the study data shows that dogs treated with Canalevia resolved their diarrhea within 24 hours of the first administration of the drug, with the data demonstrating statistical and clinical relevance compared to placebo-treated dogs."
Jaguar plans to submit a dossier to the European Medicines Agency (EMA) to outline the results of the updated analysis of the company's completed study of Canalevia in dogs with general diarrhea. If acceptable to the EMA, the company will then submit a Marketing Authorization Application (MAA) for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries.
Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs.
Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy.
About Conditional Approval and Full Approval
Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA's conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the "substantial evidence" standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving "substantial evidence of effectiveness" for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.
About Chemotherapy-induced Diarrhea (CID) in Dogs
According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost
Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.
Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.
About Canalevia®-CA1
Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a "small number" threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.
About Crofelemer
Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
Important Safety Information About Canalevia®-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Canalevia-CA1, visit canalevia.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that company personnel will attend the 2025 Animal Health Summit, Jaguar's expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in dogs with general diarrhea, Jaguar's expectation that it will submit a dossier to the EMA to outline the results of the updated analysis of the company's completed study of Canalevia in dogs with general diarrhea, Jaguar's expectation that, if the dossier is acceptable to the EMA, the company will then submit a MAA for Canalevia for general diarrhea in dogs to the EMA, and Jaguar's expectation that, if the application is approved by the EMA, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1 "Cancer in Pets." American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets
2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398
Source: Jaguar Health, Inc.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the current FDA approval status of Canalevia-CA1 for dogs?
How many dogs could potentially benefit from Canalevia's expanded indication?
What is the enrollment status of JAGX's Canalevia-CA1 effectiveness study?
How does Canalevia work differently from other diarrhea treatments for dogs?
What are Jaguar Health's three main goals for Canalevia expansion?
